Amarin Corp Plc (AMRN)

Amarin Corporation plc (NASDAQ:AMRN) is one of the best performing pharma stocks in 2025.

On January 8, Michael Yee, global head of biotech research at UBS, appeared on CNBC’s ‘Squawk on the Street’ to discuss his bullish outlook on biopharma stocks in 2026 and the pharma M&A outlook...

Operator: Welcome to Amarin Corporation's conference call to discuss its third quarter 2025 financial results.

Operator: Good morning, and welcome to Amarin Corporation's Conference Call to discuss its Second Quarter 2025 Financial Results. I would now like to turn the conference over to Mr.

Operator: Welcome to Amarin Corporation's Conference Call to discuss its First Quarter 2025 Business Update and Financial Results.

Operator: Welcome to Amarin Corporation's Conference Call to discuss its Fourth Quarter and Full Year 2024 Business Update and Financial Results.

Amarin Corporation plc (NASDAQ:AMRN) Q3 2024 Earnings Call Transcript October 30, 2024Amarin Corporation plc reports earnings inline with expectations.

Operator: Welcome to Amarin Corporation’s Conference Call to discuss its Second Quarter 2024 Business Update and Financial Results.

Amarin Corporation plc misses on earnings expectations. Reported EPS is $-0.01 EPS, expectations were $-0.0075.